2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Antibody-Oligonucleotide Conjugates (AOCs)

Antibody-Oligonucleotide Conjugates (AOCs)

ADC-Related Custom Services

Antibody-Oligonucleotide Conjugate (AOC) consists of three parts: antibody, linker and oligonucleotide. AOC combines the tissue-specific targeting of antibody drugs with the target-specific capabilities of small nucleic acids, addressing the limitation of current small nucleic acid drugs that mainly target the liver through LNP and GalNAc delivery systems.

Antibody-Oligonucleotide Conjugates (AOCs) Related Products (10):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-177564
    Delpacibart zotadirsen
    Delpacibart zotadirsen (Del-zota), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated to a phosphorodiamidate morpholino conjugate (PMO), Delpacibart zotadirsen is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Delpacibart zotadirsen is used for the study of myotonic dystrophy type 1 (DM1).
    Delpacibart zotadirsen
  • HY-177971
    Braxlosiran
    Braxlosiran, one of the components of the AOC Delpacibart braxlosiran (HY-177566), is composed of a siRNA targeting DUX4 (dual homologous box protein) and SMCC linker (HY-42360). Abnormal expression of the DUX4 protein leads to changes in gene expression in muscle cells, and these changes are associated with the loss of muscle function in facioscapulohumeral muscular dystrophy (FSHD).
    Braxlosiran
  • HY-147262
    Etedesiran
    Etedesiran is a component of the AOC drug Delpacibart etedesiran (HY-177565), formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK) with SMCC linker (HY-42360). Etedesiran carries a maleimide group at its terminus, which can react with cysteine or lysine and is used for the synthesis of AOC drugs. Etedesiran is applicable to research related to myotonic dystrophy type 1.
    Etedesiran
  • HY-177972
    Zotadirsen
    Zotadirsen, one of the components of the AOC Delpacibart zotadirsen (HY-177564), is composed of a phosphorodiamidate morpholino oligomers (PMOs) and SMCC linker (HY-42360). Zotadirsen specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Zotadirsen can be used to synthesize AOC drugs. Zotadirsen can also be used in the research of Duchenne muscular dystrophy (DM).
    Zotadirsen
  • HY-177973A
    Zoratolimod scrambled negative control
    Zoratolimod scrambled negative control is the sequence scrambled negative control of Zoratolimod.
    Zoratolimod scrambled negative control
  • HY-177971A
    Braxlosiran scrambled negative control
    Braxlosiran scrambled negative control is the sequence scrambled negative control of Braxlosiran.
    Braxlosiran scrambled negative control
  • HY-177973
    Zoratolimod
    Zoratolimod, one of the components of the AOC Mozistobart zoratolimod (HY-177568), is composed of an oligonucleotide that can activate TLR9 and linkers (HY-164181 Fmoc-protected DMT-Dt PEG2 NH2 amidite; HY-130907 Fmoc-N-PEG24-acid). Zoratolimod can be used to synthesize AOC drugs), for cancer immunology research.
    Zoratolimod
  • HY-177972A
    Zotadirsen scrambled negative control
    Zotadirsen scrambled negative control is the sequence scrambled negative control of Zotadirsen.
    Zotadirsen scrambled negative control
  • HY-147262A
    Etedesiran scrambled negative control
    Etedesiran scrambled negative control is the sequence scrambled negative control of Etedesiran.
    Etedesiran scrambled negative control
  • HY-186089
    Bis-Mal-Lysine-PEG4-DBCO
    Bis-Mal-Lysine-PEG4-DBCO (CGBS-13) is a linker for AOC drugs and can be used to synthesize AOC drugs that inhibit DMPK gene expression.
    Bis-Mal-Lysine-PEG4-DBCO